DENOVO BIOPHARMA LLC
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
A Study of Safety and Tolerability in Subjects With Schizophrenia
- First Posted Date
- 2011-05-16
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 75
- Registration Number
- NCT01354353
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glendale, California, United States
A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 678
- Registration Number
- NCT01328093
- Locations
- πΈπͺ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden
A Study of LY2140023 in Patients With Schizophrenia
- First Posted Date
- 2011-03-03
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 567
- Registration Number
- NCT01307800
- Locations
- πΊπ¦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vinnytsya, Ukraine
A Study in Schizophrenic Patients
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 82
- Registration Number
- NCT01125358
- Locations
- π¨π³
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
- Conditions
- Interventions
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 167
- Registration Number
- NCT01052103
- Locations
- πͺπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zamora, Spain
A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
- Conditions
- Interventions
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 261
- Registration Number
- NCT00845026
- Locations
- π·πΊ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Samara, Russian Federation
Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 195
- Registration Number
- NCT00149292
- Locations
- π·πΊ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Village Nikolskoe, Russian Federation